Our Approach

TriSalus’ multi-pronged approach investigating the treatment of liver metastases and pancreatic solid tumors by leveraging immunomodulation therapy or other tumor-killing agents with our FDA cleared intravascular regional delivery technology.

TriSalus Investigational Focus

Learn more about our approach by clicking on any of the circles in the diagram above. 

TriSalus multi-pronged approach which combines immunomodulation therapy or other tumor killing agents with our FDA cleared intravascular regional drug delivery system is under investigation for the treatment of liver metastases, pancreatic cancer, and other solid tumors.

Targeted Therapeutic

We believe that a comprehensive approach is needed for liver and pancreatic tumors. Our strategy involves studying optimal delivery of therapeutics into high pressure solid tumors, while using immunomodulatory approaches with the goal to help enable deeper responses to immunotherapies designed to target cancer cells. Our focus is on addressing critical issues that limit immunotherapy success in the liver and pancreas.

Immunomodulation

Leveraging our proprietary PEDD™ approach for the regional delivery of investigational SD-101, a TLR9 agonist, currently being studied for the potential to convert unresponsive tumors to responsive tumors by converting immunosuppressor cells into immunostimulant cells.

Regional Tumor-Directed Delivery

Our unique PEDD™ approach is able to perfuse a therapeutic more uniformly across the vascular bed supplying the tumor, with the potential of improving response.1,2,*

References:

  1. Data on File, Porcine Model, TriSalus Life Sciences 2020
  2. Titano, J.J., et al. Cardiovasc Intervent Radiol. 2019;42:560-568.

* Titano et al: A small, retrospective, single-center study included 88 treatment-naive patients with solitary HCC tumors <6.5 cm who underwent treatment utilizing either SIS (n = 18) or standard EH microcatheters (n = 70). Twenty-three patients (5 SIS, 18 EH) received a liver transplant during the study, with 1 SIS and 6 EH patients excluded from the tumor necrosis analysis for receiving subsequent therapies prior to transplant. A pathologist performed a blinded review of the liver explant specimens to assess tumor necrosis and treatment distribution. Pathological analysis of explanted livers showed greater concentrations of microspheres within the tumor relative to the surrounding tissue in SIS explants (88.7 ± 10.6%) versus the EH explants (55.3 ± 32.7%) (p = 0.002).

Immunomodulation

Developing investigational therapies with the potential to create a favorable tumor microenvironment and overcome immunosuppression.

Toll-Like Receptors

Our investigational TLR9 agonist may promote anti-tumor T cell function to help attack liver metastases and pancreatic solid tumors.

Drug Delivery

FDA cleared, intravascular regional infusion technology delivered therapeutic agents more precisely and deeply into tumors while protecting normal tissue.2*

References:

  1. Data on File, Porcine Model, TriSalus Life Sciences 2020
  2. Titano, J.J., et al. Cardiovasc Intervent Radiol. 2019;42:560-568.

* Titano et al: A small, retrospective, single-center study included 88 treatment-naive patients with solitary HCC tumors <6.5 cm who underwent treatment utilizing either SIS (n = 18) or standard EH microcatheters (n = 70). Twenty-three patients (5 SIS, 18 EH) received a liver transplant during the study, with 1 SIS and 6 EH patients excluded from the tumor necrosis analysis for receiving subsequent therapies prior to transplant. A pathologist performed a blinded review of the liver explant specimens to assess tumor necrosis and treatment distribution. Pathological analysis of explanted livers showed greater concentrations of microspheres within the tumor relative to the surrounding tissue in SIS explants (88.7 ± 10.6%) versus the EH explants (55.3 ± 32.7%) (p = 0.002).